Open access
63
Views
3
CrossRef citations to date
0
Altmetric
Original Research
A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy
Jing Qian1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Yingying Qian1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Jian Wang1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Bing Gu2 Department of Laboratory Medicine, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, People’s Republic of China;3 Medical Technology Institute, Xuzhou Medical College, Xuzhou, People’s Republic of China
, Dong Pei1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Shaohua He1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Fang Zhu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Oluf Dimitri Røe4 Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway;5 Department of Oncology, Clinical Cancer Research Center, Aalborg, Denmark;6 Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark;7 Department of Surgery, Cancer Clinic, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
, Jin Xu8 Department of Molecular Cell Biology and Toxicology, Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center, Nanjing Medical University, Nanjing, People’s Republic of China
, Lianke Liu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Yanhong Gu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Renhua Guo1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Yongmei Yin1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of China
, Yongqian Shu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
& Xiaofeng Chen1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Xuzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
show all
Pages 241-258
|
Published online: 24 Feb 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.